Prostate cancer test kit PROSCAN™

oncologyfor precision medicineBRCA1 gene

Urologic cancers are cancers of the urinary tract, including bladder cancer, renal (kidney) cancer and those specific to men, such as prostate cancer and testicular cancer. Prostate cancer is one of the most commonly diagnosed malignancies in men. The current treatment landscape for urologic cancers includes surgery, radiation therapy, chemotherapy and androgen deprivation therapy (ADT) for prostate cancer. Patients, however, often face recurrences and resistance to these treatments. Novel biomarkers help with prognosis of current treatments and development of targeted therapies and immunotherapies to improve therapeutic interventions. Targets 69 key genes in prostate cancer Analyzes key genes in androgen receptor pathway and PI3K-mTOR pathway Predicts efficacy and toxicity of chemotherapy based on associated genetic biomarkers Identifies androgen receptor (AR) mutations and elucidates drug resistance mechanisms Detects BRCA1/2 deficiency to predict potential response to PARP inhibitors Evaluates microsatellite instabilities (MSI) and mismatch repair deficiency (dMMR) to better inform immunotherapy decisions Assesses genetic predisposition to cancers WHO IS IT FOR Prostate cancer patients seeking personalized medicine Patients with recurrent metastatic castration-resistant prostate cancer (mCRPC) SAMPLE TYPES Tumor tissue (FFPE block/slides, or frozen tissue) Fine needle biopsy Liquid biopsy (plasma and others)